- Home
- SRRK
as 05-09-2025 12:44pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Upcoming Earnings Alert:
Get ready for potential market movements as Scholar Rock Holding Corporation SRRK prepares to release earnings report on 14 May 2025.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.1B | IPO Year: | 2018 |
| Target Price: | $42.17 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 601.05% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sacco Tracey | SRRK | Chief Commercial Officer | Apr 25 '25 | Sell | $33.15 | 5,000 | $164,130.79 | 71,834 | |
| Sacco Tracey | SRRK | Chief Commercial Officer | Mar 24 '25 | Sell | $33.30 | 6,500 | $215,014.05 | 71,834 | |
| Moore Erin | SRRK | Interim PFO and PAO | Mar 24 '25 | Sell | $33.12 | 13,564 | $449,236.97 | 82,609 | |
| Peng Katie | SRRK | Director | Mar 17 '25 | Sell | $34.42 | 1,006 | $34,626.92 | 30,319 | |
| Myles Edward H | SRRK | COO & CFO | Mar 10 '25 | Sell | $35.35 | 142,292 | $5,068,974.19 | 140,740 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 18 '25 | Sell | $37.33 | 72,645 | $2,714,767.40 | 111,084 | |
| Parlavecchio Caryn | SRRK | CHRO | Feb 18 '25 | Sell | $36.83 | 5,296 | $195,046.38 | 140,258 | |
| Backstrom Jay T. | SRRK | CHIEF EXECUTIVE OFFICER | Feb 18 '25 | Sell | $36.83 | 18,372 | $676,622.39 | 311,991 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Feb 18 '25 | Sell | $36.83 | 5,742 | $211,472.12 | 189,295 | |
| Myles Edward H | SRRK | COO & CFO | Feb 18 '25 | Sell | $36.83 | 7,809 | $287,597.66 | 140,740 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
Business Wire
3 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
4 days ago
US High Growth Tech Stocks To Watch
Motley Fool
11 days ago
Why Scholar Rock Stock Took a Knock on Monday
MT Newswires
11 days ago
Scholar Rock Names Chairman David Hallal as CEO
Business Wire
11 days ago
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
Motley Fool
16 days ago
Why Scholar Rock Holding Stock Topped the Market Today
GuruFocus.com
18 days ago
Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.